DeepMed Research

Rivastigmine

Generic Name: Rivastigmine

Brand Names: Exelon, Nimvastid, Prometax, Rivastigmine Sandoz, Rivastigmine 1 A Pharma, Rivastigmine Hexal, Rivastigmine Actavis

Drug Type: Small Molecule

Chemical Formula: C_₁₄H_₂₂N_₂O_₂

CAS Number: 123441-03-2

Unique Ingredient Identifier: PKI06M3IW0

Background: Rivastigmine is a parasympathomimetic or cholinergic agent for the treatment of mild to moderate dementia of the Alzheimer's type. Rivastigmine is a cholinesterase inhibitor that inhibits both butyrylcholinesterase and acetylcholinesterase.

Indication: For the treatment of mild to moderate dementia associated with Parkinson's disease or of the Alzheimer's type.

Associated Conditions: Dementia With Lewy Body Disease, Mild Dementia due to Parkinson's disease, Mild Dementia of the Alzheimer's Type, Moderate Alzheimer's Type Dementia, Moderate Dementia due to Parkinson's disease

Clinical Trials

Safety and Efficacy of AR1005 in Patients with Lewy Body Disease

Phase 2

Recruiting

Conditions: Lewy Body Dementia

Interventions: Drug: Placebo
Drug: AR1005
Drug: Rivastigmine 3 mg

First Posted Date: 2024-08-05

Last Posted Date: 2024-10-02

Lead Sponsor: Yonsei University

Target Recruit Count: 60

Registration Number: NCT06537076

Locations: 🇰🇷
Severance Hospital, Seoul, Korea, Republic of

Rivastigmine to Prevent Recurrence of Antimuscarinic Delirium

Phase 2

Recruiting

Conditions: Anticholinergic Toxicity

Interventions: Drug: Placebo
Drug: Rivastigmine

First Posted Date: 2024-05-06

Last Posted Date: 2024-11-06

Lead Sponsor: Washington University School of Medicine

Target Recruit Count: 42

Registration Number: NCT06399679

Locations: 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States

Rivastigmine for Antimuscarinic Delirium

Phase 2

Not yet recruiting

Conditions: Anticholinergic Toxicity

Interventions: Drug: Placebo
Drug: Rivastigmine

First Posted Date: 2024-04-24

Last Posted Date: 2024-11-06

Lead Sponsor: Washington University School of Medicine

Target Recruit Count: 42

Registration Number: NCT06382649

Locations: 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States

Rivastigmine Bioequivalence Trial With Multiple Applications of Transdermal Patches (9.5 mg/24 h)

Phase 1

Completed

Conditions: Bioequivalence

Interventions: Drug: Exelon® 9.5 mg/24 h
Drug: Rivastigmine twice-weekly 9,5 mg/24 h

First Posted Date: 2023-05-31

Last Posted Date: 2024-02-02

Lead Sponsor: SocraTec R&D GmbH

Target Recruit Count: 38

Registration Number: NCT05883124

Locations: 🇩🇪
SocraTec R&D GmbH, Clinical Pharmacology Unit, Erfurt, Thuringia, Germany

Rivastigmine Bioequivalence Trial With Multiple Application of Transdermal Patches (13.3mg/24h)

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: RID-TDS 13.3 mg/24 h
Drug: Exelon® 13.3 mg/24 h

First Posted Date: 2023-05-10

Last Posted Date: 2023-10-19

Lead Sponsor: Luye Pharma Group Ltd.

Target Recruit Count: 48

Registration Number: NCT05853341

Locations: 🇩🇪
SocraTec R&D GmbH, Clinical Pharmacology Unit, Erfurt, Thüringen, Germany

Prediction of ECT Treatment Response and Reduction of Cognitive Side-effects Using EEG and Rivastigmine

Phase 4

Recruiting

Conditions: Depressive Disorder

Interventions: Other: Sham
Drug: Rivastigmine Transdermal Product

First Posted Date: 2023-03-14

Last Posted Date: 2024-05-10

Lead Sponsor: UMC Utrecht

Target Recruit Count: 100

Registration Number: NCT05768126

Locations: 🇳🇱
UMC Utrecht, Utrecht, Netherlands

Toward a Computationally-Informed, Personalized Treatment for Hallucinations

Early Phase 1

Recruiting

Conditions: Hallucinations, Auditory
Psychosis

Interventions: Drug: Rivastigmine Transdermal System
Drug: Scopolamine
Drug: Placebo Patch

First Posted Date: 2020-04-29

Last Posted Date: 2024-07-25

Lead Sponsor: Yale University

Target Recruit Count: 35

Registration Number: NCT04366518

Locations: 🇺🇸
Connecticut Mental Health Center, New Haven, Connecticut, United States

CHIEF-PD (CHolinesterase Inhibitor to prEvent Falls in Parkinson's Disease)

Phase 3

Active, not recruiting

Conditions: Parkinson Disease

Interventions: Drug: Rivastigmine Transdermal System
Other: Placebo Transdermal System

First Posted Date: 2020-01-13

Last Posted Date: 2024-08-19

Lead Sponsor: University of Bristol

Target Recruit Count: 600

Registration Number: NCT04226248

Locations: 🇬🇧
University Hospitals Plymouth NHS Trust, Plymouth, United Kingdom
🇬🇧
NHS Forth Valley, Larbert, Scotland, United Kingdom
🇬🇧
Norfolk and Norwich University Hospital, Norwich, Norfolk, United Kingdom

and more 34 locations

Rivastigmine Patch Compared to Melatonin Patch in Prevention of Postoperative Delirium

Phase 1

Completed

Conditions: Delirium

Interventions: Drug: Rivastigmine Transdermal System [Exelon]
Drug: Melatonin

First Posted Date: 2019-12-06

Last Posted Date: 2020-07-09

Lead Sponsor: Ain Shams University

Target Recruit Count: 180

Registration Number: NCT04189666

Locations: 🇪🇬
Ain Shams University, Cairo, Abassia, Egypt

Noradrenaline, Acetylcholine and Dynamic Learning in Healthy Humans

Not Applicable

Completed

Conditions: Healthy

Interventions: Drug: Placebo oral tablet
Drug: Rivastigmine
Drug: Reboxetine

First Posted Date: 2019-05-21

Last Posted Date: 2020-06-16

Lead Sponsor: University of Oxford

Target Recruit Count: 107

Registration Number: NCT03957174

Locations: 🇬🇧
Dept of Psychiatry, University of Oxford, Oxford, Oxfordshire, United Kingdom

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy